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We aimed to determine the initial adherence of HIV cohort patients to ART (antiretroviral therapy), and reasons for non-adher-
ence. Patients who received ART at the time of enrollment in the Korea HIV/AIDS Cohort were included in this study. Treatment 
adherence was determined at the baseline interview by self-reported questionnaire. Eight-hundred thirty two HIV-infected 
patients received ART. Of these, 253 (30.4%) patients skipped ART more than once a month. The most common reason of skip-
ping medication was “simply forgot” (60.4%).
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Brief Communication
Because of the effectiveness of antiretroviral drugs, adequate 
adherence to medication is an important factor in the success 
of antiretroviral therapy (ART). Many previous studies showed 
that poor adherence to medication led to failure of viral sup-
pression and poor recovery of CD4+ T cells [1, 2]. Poor adher-
ence causes low CD4+ cell levels and low CD4+ cell levels are 
obviously associated with opportunistic infections [3]. In addi-
tion, treatment failure due to poor adherence can mislead phy-
sicians, resulting in an unnecessary change of ART [4]. Causes 
affecting adherence have been studied in other countries [5]. 
In Korea, some studies have examined adherence to medica-
tion in HIV-infected patients, but a limited population was 
studied [6-8]. Thus, we evaluated the degree of adherence to 
medication and causes of non-adherence in Korea using the 
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Korea Human Immunodeficiency Virus and Acquired Im-
mune Deficiency Syndrome (HIV/AIDS) Cohort data.
T﻿﻿he Korea HIV/AIDS Cohort Study was initiated in 2006, and 
is a prospective observational study in South Korea. HIV-in-
fected patients older than 18 years were registered the cohort 
after obtaining informed consent. Trained study nurses with 
supervision of infectious diseases physicians from all hospitals 
collected information every 6 month, using standardized sur-
vey form. T﻿﻿he survey form of the cohort study is divided into 
six categories and consists of about 270 items; socioeconomic 
status, medical history, information of HIV/AIDS infection and 
treatment, opportunistic infection, physical findings, and labo-
ratory results including virological and immunological status. 
In the category of HIV/AIDS infection and treatment, the in-
formation included history of HIV infection, presence of HIV 
relating/defining diseases, history of antiretroviral therapy, 
mutation of antiretroviral drugs, and treatment adherence in 
the most recent 3 months. T﻿﻿he treatment adherence consists of 
four questionnaires; current ART prescription status, frequen-
cy of skipping ART, reasons of skipping ART (multiple respons-
es), and ranking of reasons for skipping ART. Institutional re-
view board approval was obtained from all participating 
hospitals.
In this study, using the baseline data of the Korea HIV/AIDS 
cohort at the time of enrollment, we investigated the treatment 
adherence, from December 2006 to October 2015. In the co-
hort patients, we included the patients receiving ART at the 
time of enrollment. We investigated frequency of skipping an-
tiretroviral drugs. And we divided into the two groups by fre-
quency of skipping; one group is patients taking ART without 
skipping, and the other who were taking medicine with skip-
ping more than one time or did not answer specific response. 
Except for patients taking ART without skipping, study patients 
researched reasons for skipping medicine and self-ranking of 
the reasons. Student's t-test or the Wilcoxon rank-sum test was 
used to analyze continuous variables, and the Chi-square test 
or Fisher exact test was used for categorical variables. Statisti-
cal analyses were performed using R statistics ver. 3.2.1, and P 
< 0.05 was considered statistically significant.
A total of 1,356 HIV-infected patients were enrolled in the co-
hort study. Of these, 832 (61.4%) received ART at the time of 
enrollment in the cohort. T﻿﻿he number of male and female pa-
tients were 778 (93.5%) and 54 (6.5%), respectively. Of the 832 
patients, 537 (64.5%) were taking medicine without skipping 
medicine. Other 253 (30.4%) patient skipped ART more than 
one time. And, 42 (5.1%) patients did not give specific answer 
to the questionnaires. Table 1 shows the baseline characteris-
tics of study population. Median age was 43 years (interquar-
tile range [IQR], 34-51) Median value of CD4+ T cell count was 
385 cells/mm3 (IQR, 235-552) and the median value of HIV-
RNA titer was 28 copies/mL (IQR, 19-137.5). Six hundred sev-
enty-one patients took medicine twice a day. The median 
number of tablets per day was 5 (IQR, 3-7) (Table 1).
Table 2 shows the frequency of skipping. T﻿﻿he most reported 
frequency of skipping was once a month, in 108 patients 
(108/832, 12.98%). T﻿﻿he next most reported frequency was once 
a week (50/832, 6.01%). T﻿﻿he reasons for skipping ART are pre-
sented in Table 3. “Simply forgot” was the most common rea-
son (177, 60.4% of respondents). Side effects of antiretroviral 
drugs were reported second most common reason (24, 8.1%). 
Other reasons for skipping included being away from home, 
not eating a meal, fear of revealing the diagnosis to others, 
drinking alcohol, being busy, misinformation about ART, miss-
ing a visit to the outpatient clinic, poor economic status, lack of 
motivation, too many pills, other acute illness, and herbal 
medication. Forty-one patients did not give specific answer to 
this question (14.0%) (Table 3). In the result of the ranking of 
reasons for skipping ART, question to know the importance of 
each reason to skip medication, “Simply forgot” was the high-
est ranked reason (168/295, 56.9%), followed by side effects of 
antiretroviral drugs (18/295, 6.1%).
We conducted an analysis according to age group. In all age 
groups, “simply forgot” was the most common reason. In the 
20s and 30s groups, fear of revealing the diagnosis was the sec-
ond most common reason: 4 in their 20s (4/38, 10.5%) and 8 in 
their 30s (8/93, 8.6%). In the 40s group, a side effect was the 
second most common reason (10/92, 10.9%). Being away from 
home including travel was the second most frequently report-
ed reason in the 50s and 60s groups: 5 in their 50s (5/55, 9.1%) 
and 4 in their 60s (4/16, 25%).
Achieving a high level of adherence is important in the man-
agement of any chronic disease. In HIV/AIDS, good adherence 
is equally critical for long-term viral suppression. Studies of 
treatment adherence have been conducted in various coun-
tries. T﻿﻿he Adult AIDS Clinical Trials Group (AACTG) reported 
that 63% of 93 enrolled patients showed >95% adherence [2]. 
In China, 80.7% of patients took all antiretroviral drugs, and 
those with adherence rates of 95-99% and 90-94% accounted 
for 15.5% and 1.9%, respectively [9]. A meta-analysis evaluated 
84 observational studies performed in 20 countries, and found 
that 62% reported ≥90% ART adherence [10]. One report evalu-
ated adherence in Korea. In this study, 53.1% of patients (26 of 
49) reported regular adherence to antiretroviral drugs [7]. In 
our study, 64.5% of patients took medicine every day, without 
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Table 1. Baseline characteristics of study population
Characteristic
Total 
(n = 790)
Skipping ART (-)
(n = 537)
Skipping ART (+)
(n = 253)
P-value
Median age, yr 43 (34-51) 44 (34-53) 42 (34-49) 0.038
Male 0.134
MSM 211 (26.7) 137 (25.5) 74 (29.2)
MSW 287 (36.3) 194 (36.1) 93 (36.8)
Bisexual man 59 (7.5) 35 (6.5) 24 (9.5)
Female 51 (6.5) 40 (7.4) 11 (4.3) 0.134
Marriage status 0.039
Single 421 (53.3) 269 (50.1) 152 (60.1)
Married 214 (27.1) 155 (28.9) 59 (23.3)
Separation 15 (1.9) 10 (1.9) 5 (2.0)
Divorce 69 (8.7) 45 (8.4) 24 (9.5)
Bereavement 12 (1.5) 8 (1.5) 4 (1.6)
Cohabitation 11 (1.4) 10 (1.9) 1 (0.4)
Smoking, current 329 (41.6) 195 (36.3) 134 (53.0) <0.0001
Alcohol, current 370 (46.8) 222 (41.3) 148 (58.5) <0.0001
Underlying diseases
Diabetesa 45 (5.8, 9) 29 (5.5, 5) 16 (6.4, 4) 0.747
Dyslipidemiaa 106 (13.7, 22) 58 (11, 10) 48 (19.4, 12) 0.002
Metabolic syndromea 3 (0.4, 2) 1 (0.2, 1) 2 (0.8, 1) 0.507
Lipodystrophya 27 (3.4, 25) 20 (3.8, 20) 7 (2.8, 5) 0.621
Osteoporosisa 7 (0.9, 2) 3 (0.6, 2) 4 (1.6, 0) 0.309
Hypertensiona 80 (10.3, 16) 52 (9.9, 11) 28 (11.1, 5) 0.683
Myocardial Infarction 4 (0.5) 2 (0.4) 2 (0.8) 0.817
Angina 4 (0.5) 2 (0.4) 2 (0.8) 0.817
Cerebral Infarction 6 (0.8) 6 (1.1) 0 (0) 0.210
Cerebral hemorrhage 3 (0.4) 1 (0.2) 2 (0.8) 0.506
Hepatitis Ba 39 (5.0, 15) 27 (5.1, 10) 12 (4.8, 5) 0.976
Hepatitis Ca 9 (1.1, 3) 6 (1.1, 3) 3 (1.2, 0) 1.000
Fatty liver 13 (1.7) 9 (1.7) 4 (1.6) 1.000
Liver cirrhosis 7 (0.9) 3 (0.6) 4 (1.6) 0.309
CKD with HD 1 (0.1) 0 (0) 1 (0.4) 0.702
CKD with PD 1 (0.1) 0 (0) 1 (0.4) 0.702
Median CD4+ T cell count (cells/mm3) 385 (235-552) 384 (225-552) 392 (254-553) 0.339
Median HIV-RNA (copies/mL) 28 (19-137.5) 30 (19-150) 25 (19-131) 0.936
Opportunistic infectionb 232 (29.4) 150 (27.9) 82 (32.4) 0.228
Prophylaxis of opportunistic infectionb 106 (13.4) 75 (14.0) 31 (12.3) 0.584
ART regimen 0.355
PI 70 (8.9) 45 (8.5) 25 (10.0)
Boosted PI 394 (50.3) 258 (48.5) 136 (54.2)
NNRTI 234 (29.9) 165 (31.0) 69 (27.5)
NRTI 4 (0.5) 4 (0.8) 0 (0)
INI 66 (8.4) 49 (9.2) 17 (6.8)
Others 15 (1.9) 11 (2.1) 4 (1.6)
Number of tablets/day 5 ( 3-7) 5 (3-7) 5 ( 3-7) 0.612
Number of daily doses 0.018
1 times/day 99 (12.6) 79 (14.8) 20 (8.0)
2 times/day 671 (85.7) 443 (83.3) 228 (90.8)
3 times/day 13 (1.7) 10 (1.9) 3 (1.2)
Past ART history 444 (56.2) 267 (49.7) 177 (70.0) <0.0001
Number of past ART regimen 2 (1-3) 1 (1-3) 2 (1-3) 0.023
Experience of treatment failure 54 (12.2) 25 (9.4) 29 (16.4) 0.039
Median duration of current ART (day) 226.5 (68-541) 212 (60-523) 259.0 (98-546) 0.047
Median duration of total ART (day) 516.5 (149-1,331) 395 (96.5-1,049.0) 784 (298.5-1,952) <0.0001
Values are presented as number (%) or median (interquartile range).
aThese valuses are percentage and the number of patients being treated.
bOpportunistic infection included Pneumocystis jirovecii  infection, Toxoplasma gondii  infection, Candida  infection Cryptococcus neoformans  infection, Salmonella  infection, tuberculo-
sis, and cytomegalovirus infection.
ART, antiretroviral therapy; MSM, men who have sex with men; MSW, men who have sex with women; CKD, chronic kidney disease; HD, hemodialysis; PD, peritoneal dialysis; HIV, 
human immunodeficiency virus; RNA, ribonucleic acid; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; 
INI, integrase inhibitor.
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skipping during the prior 3 months, and 108 were skipped ART 
only once a month. There was improvement in adherence 
compared to past reports. T﻿﻿he rate of adherence was similar to 
that of other countries. 
Results of questionnaire surveys investigating the reasons for 
non-adherence were similar in various studies. The AACTG 
and the Danish Cohort Study showed that simple forgetfulness 
was the most frequently reported reason for skipping ART [5, 
11, 12]. Being away from home, change from daily routine, and 
being busy were also highly associated with skipping ART  [5, 
11, 12]. Other studies from Hong Kong, China, Costa Rica, and 
Italy showed similar results [9, 13-15]. Our study found that 
“simply forgot” was the most common self-reported reason for 
skipping ART, which is consistent with the findings of previous 
studies. However, a side effect was the second most common 
reason given for skipping ART, and was ranked higher than in 
other studies. Other reasons given were similar to those from 
other countries. Pill numbers and side effects were factors re-
lated to the antiretroviral drug itself. Otherwise, most items re-
flected lack of understanding of the disease. We should pro-
mote adherence through education and counseling. In our 
study, the most common reason given for skipping ART was 
“simply forgot” in all age groups. However, the next most fre-
quent reason was different in each age group. Therefore, tai-
lored individual counseling should be performed for success-
ful treatment.
A change in adherence over time was reported by the AIDS 
Clinical Trials Group (ACTG) and the Royal Free Clinic Cohort 
[2, 16]. Their results did not show a similar trend. The ACTG 
assessed adherence every 4 weeks until week 24. The adher-
ence rate decreased over time [2]. T﻿﻿he Royal Free Clinic Cohort 
assessed adherence every 6 months. Adherence slightly in-
creased over time [16]. T﻿﻿he Korea HIV/AIDS Cohort Study in-
vestigated the data for each 6-month period. We reviewed the 
initial data at the time of patient enrollment. It is necessary to 
understand the long-term trend in adherence by Korean 
HIV-infected patients. Therefore, additional analysis will be 
needed using follow-up data. 
In our study, a substantial portion of responses to each ques-
tion was “no specific response”. Unlike other reports, the side 
effects of antiretroviral drugs were the second most common 
reasons for skipping ART. Side effects should be an important 
factor in Korea. However, being busy or a change in daily 
schedule, which were frequently reported reasons in other 
countries, might be underestimated by “no specific response”. 
T﻿﻿his was a limitation of the self-reported questionnaire. More-
over, median value of HIV-RNA titer was low level, which 
showed no difference between patients group who skipped 
drug more than one time and the other group. Patients partici-
pating in the cohort were likely to be cooperative with the phy-
sicians. It was estimated that most cohort populations have 
low viral load. Therefore, we thought that ‘simply forgot’ did 
Table 2. Frequency of skipping antiretroviral drugs
Frequency of skipping antiretrovirals Patients (%)a
Never once 537 (64.5)
Once a month 108 (13.0)
Once a week 50 (6.0)
Once in 2 weeks 43 (5.2)
No specific response 42 (5.0)
More than twice in one week 29 (3.6)
Daily 8 (1.0)
Once in 2-3 monthsb 7 (0.8)
Irregularityb 6 (0.7)
Othersb,c 2 (0.2)
aValues are presented as percentage of total study population (n=832).
bThis frequency was answered by the respondents in free text.
cThese patients skipped antiretroviral therapy for 25 days and 13 days, respec-
tively.
Table 3. Reasons for skipping antiretroviral therapy (multiple responses)
Reasons Frequency (%)a
Simply forgot 177 (60.4)
No specific response 41 (14.0)
Side effects of antiretroviral drugs 24 (8.1)
Being away from home 22 (7.5)
Not eating a meal 18 (6.1)
Fear of revealing diagnosis to others 17 (5.8)
Drinking alcohol 17 (5.8)
Busy 9 (3.1)
Misinformation about ART 5 (1.7)
Missing a visit to outpatient clinicb 4 (1.4)
Low socioeconomic status 3 (1.0)
Lack of motivationb 3 (1.0)
Other acute illnessb 3 (1.0)
Too many pills 3 (1.0)
Herbal medicationb 1 (0.3)
Total 347
aValues are presented as percentage of respondents (n = 295).
bThese were answered by the respondents in free text.
ART, antiretroviral therapy.
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not reach clinical significance in this study population. We 
thought that the cohort population did not fully reflect the 
treated Korea HIV-infected patients, which was considered a 
limitation in the interpretation of this study. Nevertheless, we 
think that our study data will aid in the understanding of treat-
ment adherence and contributory factors in Korean HIV-in-
fected patients. 
In conclusion, among the Korea HIV/AIDS cohort, about 
30% of patients skipped antiretroviral drug more than once a 
month. T﻿﻿he most common reason of skipping medication was 
“simply forgot”.
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